J&J's Actelion buyout pays off again with approval of Opsynvi in pulmonary arterial hypertension
Johnson & Johnson scored an FDA approval for Opsynvi, a combo of the endothelin receptor antagonist Opsumit and the phosphodiesterase 5 inhibitor tadalafil, for the treatment of pulmonary arterial hypertension.
The combo is approved both for patients in the first-line setting as well as those who have already been treated with Opsumit and tadalafil as separate tablets. J&J owns Opsumit through its buyout of Actelion and tadalafil is the active ingredient of an Eli Lilly drug (Cialis) that has since hit the generic market. Opsumit is a blockbuster drug that brought in $1.9 billion in 2023 and was first approved in 2013 to treat pulmonary arterial hypertension. It faces a 2025 patent cliff.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
